Our Work in Gastroenterology
Targeted biologics, the recent emergence of innovative new oral therapies, and the arrival of biosimilars will continue to fuel monumental shifts in the way patients with auto-immune disorders are managed. More than ever, for both existing brands & pipeline products, future success will require a deep understanding of this complex and rapidly evolving landscape.
Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis
Board of Advisors
The primary objectives of advocacy groups are to educate, advocate, collaborate, and improve the efficiency of services for individuals with diseases in gastroenterology and those who are close to them.
Gastroenterologists Are Gearing Up to Incorporate Novel Oral Agents, Such As Pfizer’s Xeljanz, into the Treatment Paradigm for Ulcerative Colitis, According to Latest Data from Spherix Global Insights – March 23, 2018
JAK Inhibitors Expected to Introduce Fierce Competition to Treatment Paradigms Across a Wide Range of Autoimmune Indications, Including Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, and Lupus – January 10, 2018
Takeda’s Entyvio Defends Share Against Janssen’s Stelara in the Crohn’s Disease Market, and Pressure in the Ulcerative Colitis Market May Heat Up in Early 2018 if Pfizer’s Xeljanz Secures an FDA Wina – November 21, 2017
Advances in Inflammatory Bowel Diseases 2017